Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,025 public trials 2,027 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma

NCT00596154

Conditions
CNS Brain Cancer, CNS Lymphoma, Hemic and Lymphatic Diseases, +9 more
Locations
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Completed

Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients

NCT02812706

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Investigational Site Number :392001 Nagoya, Aichi-ken, Japan
  • Investigational Site Number :392005 Shibukawa-shi, Gunma, Japan
  • Investigational Site Number :392010 Hiroshima, Japan
  • Investigational Site Number :392015 Kanazawa, Ishikawa-ken, Japan
View all 13 locations
View Trial Details
Completed

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

NCT02891811

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Medizinische Universitaet Graz, Univ.-Klinik f. Innere Medizin, Onkologie Graz, Austria
  • Med. Universität Innsbruck, Univ.-Klinik f. Innere Medizin V, Hämatologie u. Onkologie Innsbruck, Austria
  • Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik Kufstein, Austria
  • LKH Hochsteiermark - Standort Leoben Abteilung für Innere Medizin und Hämatologie und internistische Onkologie Leoben, Austria
View all 21 locations
View Trial Details
Completed

Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

NCT05321147

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Alabama at Birmingham- O'Neal Comprehensive Cancer Center Birmingham, Alabama, United States
  • University of California at Irvine - Chao Family Comprehensive Cancer Center Orange, California, United States
  • Goshen Health- Goshen Hospital Goshen, Indiana, United States
  • Indiana University School of Medicine Indianapolis, Indiana, United States
View all 20 locations
View Trial Details
Completed

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT04052997

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Hodgkin Disease, +12 more
Locations
  • Mayo Clinic - Arizona Scottsdale, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UCSF Health - Hematology and Blood and Marrow Transplant Clinic San Francisco, California, United States
  • Stanford University Medical Center Stanford, California, United States
View all 73 locations
View Trial Details
Completed

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

NCT03329950

Conditions
Adenocarcinoma, Adnexal Diseases, Bile Duct Diseases, +120 more
Locations
  • HonorHealth Research Insititute Scottsdale, Arizona, United States
  • Northside Hospital, Inc. Atlanta, Georgia, United States
  • Georgia Cancer Center at Augusta University Augusta, Georgia, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists Omaha, Nebraska, United States
View Trial Details

Related conditions